Ibrutinib is a pill taken by mouth that blocks a protein called Bruton’s tyrosine kinase (BTK). This protein helps certain blood cancer cells grow, so stopping it can slow the disease. In the trial, patients receive this medication to see how well it works at different treatment intensities.

Linvoseltamab is given through an intravenous infusion, which means it is delivered directly into a vein over a short period. It is a type of targeted antibody therapy that attaches to specific cells involved in blood cancers. The study tests how effective it is when used at various dose levels.

Elranatamab is administered as a subcutaneous injection, which is an injection just under the skin. It is a monoclonal antibody designed to recognize and attack cancer cells in the blood. The trial evaluates its safety and how well it works when the dose is adjusted.

Zanubrutinib is an oral medication, taken as a pill, that also blocks the BTK protein, similar to ibrutinib. By inhibiting this pathway, it can help control the growth of certain blood cancers. In the study, different dosing strategies are compared to find the best balance of benefit and side effects.

Teclistamab is delivered by subcutaneous injection. It is a bispecific antibody, meaning it can bind to two different targets at once—helping the immune system recognize and kill cancer cells. The trial examines how changing the amount given affects outcomes for patients.

Talquetamab is also given as a subcutaneous injection. This bispecific antibody connects immune cells to cancer cells, encouraging the body’s own defenses to attack the disease. Researchers are testing various dose levels to determine the optimal treatment intensity.

Chronic lymphocytic leukemia – a type of blood cancer that starts in the bone marrow and creates many abnormal white blood cells. These cells grow slowly and can build up in the blood, lymph nodes, and spleen. Over time the number of healthy blood cells may fall, leading to fatigue or easy bruising. The disease often progresses in stages, with each stage showing more abnormal cells than the previous one.

Mantle cell lymphoma – a cancer that begins in a part of the immune system called the mantle zone of lymph nodes. It creates clusters of abnormal lymph cells that can spread to other lymph nodes, the spleen, and sometimes the bone marrow. As the disease advances, the affected areas may become larger and cause swelling. The pattern of growth can be steady or may speed up, showing more widespread involvement.

Waldenström macroglobulinemia – a disorder where the bone marrow makes too many abnormal white blood cells that produce a large protein called IgM. The excess protein can make the blood thicker, and the abnormal cells may collect in the spleen and lymph nodes. Over time the amount of IgM and the number of abnormal cells can rise, leading to larger organ size and more noticeable symptoms. The condition usually follows a slow, step‑by‑step course.

Multiple myeloma – a cancer of plasma cells, which are a type of white blood cell that normally makes antibodies. The malignant plasma cells grow in the bone marrow and can cause damage to bones and affect blood cell production. As the disease progresses, more bone areas may be involved and the amount of abnormal cells in the marrow increases. The pattern of growth can be gradual, with periods of slower change followed by faster expansion.